MiMedx Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Announce Investigation of MiMedx Group, Inc.

DALLAS--(BUSINESS WIRE)--Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that the firms are investigating potential legal claims against the officers and Board of Directors of MiMedx Group, Inc. (“MiMedx”) (NasdaqCM: MDXG) for potential breaches of fiduciary duties and violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On September 4, 2013, MiMedx confirmed its receipt of an “Untitled Letter” from the Food and Drug Administration. The letter alleged that MiMedx’s Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing drugs at one of its plants, and thereby marketed unapproved biologics products. Upon the release of this information, MiMedx’s stock fell more than 36%.

If you are an affected MiMedx shareholder and want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, [phone], or via email at [e-mail], or Zach Groover at Powers Taylor LLP, toll free [phone], via e-mail at [e-mail]. There is no cost or fee to you.

According to shareholder rights attorney Willie Briscoe, “The recent revelations that MiMedx may have violated the Public Health Service Act by facilitating the unlawful production of drugs at one of its plants has led our firms to investigate possible breaches of fiduciary duties and other violations of state and federal law by MiMedx’s officers and directors.”

The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.